JP6836506B2 - 細菌性呼吸器感染症を処置するためのピオシン類の肺投与 - Google Patents

細菌性呼吸器感染症を処置するためのピオシン類の肺投与 Download PDF

Info

Publication number
JP6836506B2
JP6836506B2 JP2017535141A JP2017535141A JP6836506B2 JP 6836506 B2 JP6836506 B2 JP 6836506B2 JP 2017535141 A JP2017535141 A JP 2017535141A JP 2017535141 A JP2017535141 A JP 2017535141A JP 6836506 B2 JP6836506 B2 JP 6836506B2
Authority
JP
Japan
Prior art keywords
piocin
piosin
mice
treated
piocins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017535141A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017529398A5 (cg-RX-API-DMAC7.html
JP2017529398A (ja
Inventor
ウォーカー，ダニエル
マッコーイー，ローラ
Original Assignee
ザ ユニバーシティー コート オブ ザ ユニバーシティー オブ グラスゴー
ザ ユニバーシティー コート オブ ザ ユニバーシティー オブ グラスゴー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ユニバーシティー コート オブ ザ ユニバーシティー オブ グラスゴー, ザ ユニバーシティー コート オブ ザ ユニバーシティー オブ グラスゴー filed Critical ザ ユニバーシティー コート オブ ザ ユニバーシティー オブ グラスゴー
Publication of JP2017529398A publication Critical patent/JP2017529398A/ja
Publication of JP2017529398A5 publication Critical patent/JP2017529398A5/ja
Application granted granted Critical
Publication of JP6836506B2 publication Critical patent/JP6836506B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017535141A 2014-09-23 2015-09-22 細菌性呼吸器感染症を処置するためのピオシン類の肺投与 Active JP6836506B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1416788.6A GB201416788D0 (en) 2014-09-23 2014-09-23 Therapeutic applications for pyocins
GB1416788.6 2014-09-23
PCT/EP2015/071768 WO2016046218A1 (en) 2014-09-23 2015-09-22 Pulmonary administration of pyocins for treating bacterial respiratory infections

Publications (3)

Publication Number Publication Date
JP2017529398A JP2017529398A (ja) 2017-10-05
JP2017529398A5 JP2017529398A5 (cg-RX-API-DMAC7.html) 2018-10-25
JP6836506B2 true JP6836506B2 (ja) 2021-03-03

Family

ID=51869352

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017535141A Active JP6836506B2 (ja) 2014-09-23 2015-09-22 細菌性呼吸器感染症を処置するためのピオシン類の肺投与

Country Status (7)

Country Link
US (2) US11643442B2 (cg-RX-API-DMAC7.html)
EP (1) EP3200813B1 (cg-RX-API-DMAC7.html)
JP (1) JP6836506B2 (cg-RX-API-DMAC7.html)
CN (1) CN107073073B (cg-RX-API-DMAC7.html)
CA (1) CA2962117C (cg-RX-API-DMAC7.html)
GB (1) GB201416788D0 (cg-RX-API-DMAC7.html)
WO (1) WO2016046218A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11857606B2 (en) 2017-12-14 2024-01-02 Bactoclear Holdings Pte. Ltd. Therapeutic bacteriocins
US20220024992A1 (en) * 2018-11-02 2022-01-27 The Rockefeller University Compositions and methods comprising lysocins as bioengineered antimicrobials for use in targeting gram-negative bacteria
EP3957995A1 (en) * 2018-11-19 2022-02-23 Bioaster Methods and reagents for multiplex binding experiments
WO2020245376A1 (en) * 2019-06-06 2020-12-10 Nomad Bioscience Gmbh Klebicins for the control of klebsiella
EP4248987A1 (en) * 2022-03-21 2023-09-27 Nomad Bioscience GmbH Chimeric bacteriocins and method for the control of pseudomonas

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861754A (en) 1986-05-28 1989-08-29 Farkas Himsley Hannah Bacteriocins and compositions thereof in anti-viral treatment
JP3655645B2 (ja) * 1992-02-28 2005-06-02 中外製薬株式会社 経粘膜投与剤
ATE202481T1 (de) * 1996-11-15 2001-07-15 Pathogenesis Corp Reines, biologisch aktives colistin, seine bestandteile und eine colistin-zubereitung zur behandlung von entzündungen der atemwege
WO2001014579A2 (en) * 1999-08-26 2001-03-01 Vion Pharmaceuticals, Inc. Compositions and methods for delivery of an agent using attenuated salmonella containing phage
US20060229244A1 (en) * 2004-09-27 2006-10-12 Robert Dorit Engineered bacteriocins and bacteriocin combinations and methods for treating bacterial based infections
US7700729B2 (en) * 2006-05-15 2010-04-20 Avidbiotics Corporation Modified bacteriocins and methods for their use
JP5603070B2 (ja) * 2006-05-15 2014-10-08 アビッドバイオティクス コーポレイション 改変バクテリオシン及びその使用方法
US20110129438A1 (en) * 2006-06-28 2011-06-02 James Robert Swartz Immunogenic protein constructs
US20080286236A1 (en) * 2007-05-14 2008-11-20 Avidbiotics Corporation Inhibition of yersinia pestis
CA2833176C (en) * 2011-04-12 2023-05-16 C.B. Appaiah Chimeric antibacterial polypeptides
GB201116234D0 (en) * 2011-09-20 2011-11-02 Aseptika Ltd Biomarkers for respiratory infection

Also Published As

Publication number Publication date
EP3200813A1 (en) 2017-08-09
CA2962117C (en) 2023-04-25
CA2962117A1 (en) 2016-03-31
US12162911B2 (en) 2024-12-10
US20170240602A1 (en) 2017-08-24
US11643442B2 (en) 2023-05-09
GB201416788D0 (en) 2014-11-05
CN107073073A (zh) 2017-08-18
US20230303636A1 (en) 2023-09-28
CN107073073B (zh) 2021-07-09
WO2016046218A1 (en) 2016-03-31
EP3200813B1 (en) 2021-04-07
JP2017529398A (ja) 2017-10-05

Similar Documents

Publication Publication Date Title
US12162911B2 (en) Pulmonary administration of pyocins for treating bacterial respiratory infections
Wang et al. A phage lysin fused to a cell-penetrating peptide kills intracellular methicillin-resistant Staphylococcus aureus in keratinocytes and has potential as a treatment for skin infections in mice
US20100254950A1 (en) Bacteriophage or lytic protein derived from the bacteriophage which effective for the treatment of staphylococcus aureus biofilm
Chee et al. Epinecidin-1, an antimicrobial peptide derived from grouper (Epinephelus coioides): Pharmacological activities and applications
CN106659748B (zh) 不动杆菌属溶素
AU2013288416B2 (en) Colicins for treating bacterial infections
CN115397994B (zh) 新型多肽、融合多肽和包含其的抗革兰氏阴性菌的抗生素
US20190111106A1 (en) Compositions for inhibiting formation of and/or disrupting bacterial biofilms and methods of use therefor
US20210330738A1 (en) Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteria
US20220227818A1 (en) Klebicins for the control of klebsilella
Safarpour-Dehkordi et al. A comprehensive investigation of the medicinal efficacy of antimicrobial fusion peptides expressed in probiotic bacteria for the treatment of pan drug-resistant (PDR) infections
CN110714000A (zh) 一种Toll样受体配体蛋白在抗细菌感染中的应用
CN100485038C (zh) 小型化抗耐药金黄色葡萄球菌多肽及其应用与制备方法
JP2019510519A5 (cg-RX-API-DMAC7.html)
HK1241754B (en) Pulmonary administration of pyocins for treating bacterial respiratory infections
US20220193186A1 (en) Method of treating and preventing bone and joint infections
Lokesh et al. Phage as medicine for bacterial diseases
WO2016146037A1 (zh) 用于抑制/瓦解生物被膜的抑制剂及其应用
Odland IDWeek 2019
Odland IDWeek 2019. Washington, DC, USA-October 2-6, 2019
McGillivary et al. RSV-induced dysregulation of expression of a mucosal β-defensin augments colonization of the upper airway by nontypeable Haemophilus influenzae
Sharma et al. Antimicrobial Resistance in Acinetobacter baumannii: A Challenge to Clinical Settings
HK40040296A (en) Therapeutics bacteriophage compositions for treating staphylococcus infection
WO2021211303A1 (en) Antiviral, bacteriophage-derived polypeptides and their use against viruses
Lee Lee JH, Park M, Park KS, Bae IK, Kim YB, Cha CJ, Jeong BC and Lee SH (2017) Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180912

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190528

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200512

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200811

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201112

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210113

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210205

R150 Certificate of patent or registration of utility model

Ref document number: 6836506

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250